Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients simply because they report cannabis use alongside alcohol or other substance use disorders.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by evaluating whether evidence-based trauma-focused treatments maintain efficacy in the substantial proportion of PTSD+SUD patients who use cannabis, a population often excluded from or underrepresented in treatment trials. The findings clarify whether clinicians should modify standard PTSD protocols for cannabis-using patients or whether existing treatments remain effective despite concurrent use, which has immediate implications for treatment planning and patient outcomes in dual-diagnosis populations.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis provides valuable data on an understudied population, the modest sample size (drawn from only four of thirty-six trials) and heterogeneity in cannabis use patterns—ranging from occasional to dependent use—limit our ability to draw definitive conclusions about treatment efficacy in cannabis-using patients with co-occurring PTSD and substance use disorders. The analysis cannot fully disentangle whether observed treatment differences reflect cannabis’s direct neurobiological effects on trauma processing, confounding factors such as self-medication severity or treatment engagement, or differences in baseline PTSD symptom profiles among cannabis users. Additionally, the predominance of cognitive-behavioral and pharmacological interventions in these trials may not capture outcomes specific to cannabis-dependent individuals, who may benefit from modified delivery or adjunctive strategies. Despite these limitations, this work appropriately flags that trauma-focused treatments show promise across cannabis use statuses, suggesting that active cannabis use need not automatically exclude patients from evidence-based PTSD treatment—though clinicians should remain alert to potential
| |